Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Catalyst Bio (NQ: CBIO)
10.96 USD  +0.20 (+1.86%)
Official Closing Price  /  Updated: 6:55 PM EST, Nov 16, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 269,800
Open 10.68
Bid (Size) 10.55 (20)
Ask (Size) 11.17 (10)
Prev. Close 10.76
Today's Range 10.33 - 11.17
52wk Range 5.050 - 36.50
Shares Outstanding 11,935,169
Dividend Yield N/A
Performance
YTD
-23.73%
-23.73%
1 Month
+11.27%
+11.27%
3 Month
+6.72%
+6.72%
6 Month
-59.47%
-59.47%
1 Year
+84.82%
+84.82%
Top News
More News
Catalyst Biosciences Announces Presentation at the 60th American Society of Hematology Annual Meeting & Exposition
Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that Dr. Howard Levy,... Read More
from GlobeNewswire News Releases
Catalyst Biosciences Reports Third Quarter Operating & Financial Results and Provides a Corporate Update
Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced operating and financial results for the third quarter ending September 30, 2018 and provided a corporate update. Read More
from GlobeNewswire News Releases
More News
Read More
Factors of Influence in 2018, Key Indicators and Opportunity within StoneMor Partners, Catalyst Biosciences, Kennametal, Emergent Biosolutions, Kimball International, and Tailored Brands — New Researc
from GlobeNewswire News Releases
Catalyst Biosciences Receives A Notice of Allowance from The Japan Patent Office Covering Modified Factor X Polypeptides
from GlobeNewswire News Releases
Catalyst Biosciences to Present at Two Upcoming Healthcare Investor Conferences
from GlobeNewswire News Releases
Market Trends Toward New Normal in Shutterstock, CrossAmerica Partners LP, Allegiance Bancshares, Portola Pharmaceuticals, StoneMor Partners, and Catalyst Biosciences — Emerging Consolidated Expectati
from GlobeNewswire News Releases
Catalyst Biosciences Announces Publication of Marzeptacog Alfa (Activated) Phase 1 Data in The Journal of Thrombosis and Haemostasis
from GlobeNewswire News Releases
Catalyst Biosciences to Present at H.C. Wainwright & Co. 20th Annual Global Investment Conference
from GlobeNewswire News Releases
Report: Developing Opportunities within The Providence Service, NVE, StoneMor Partners, Midland States, Destination XL Group, and Catalyst Biosciences — Future Expectations, Projections Moving into 20
from GlobeNewswire News Releases
Catalyst Biosciences Announces Updated Positive Interim Data at the 2018 Hemophilia Drug Development Summit
from GlobeNewswire News Releases
Catalyst Biosciences Announces Oral Presentation at the 2018 Hemophilia Drug Development Summit
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.